| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
In order to develop the prevention and/or treatment of diabetic peripheral neuropathy, which is placed on the high level of the unmet medical needs in Japan, I found Goshajinkigan as a candidate using Kampo medicines that we can use as one of medical data bases. Especially, this is the first time to demonstrate that Goshajinkigan improves a decrease in sensation appeared in later stages of diabetic peripheral neuropathy in streptozocin-induced type I diabetes mice. This significant effect is dose-dependent and reached at maximum 60 min after oral administration. Moreover, I clearly reveal that Goshajinkigan improves a decrease in sensation through the production of nitric oxide and then show the possibility that Goshajinkigan provides the substrate for nitric oxide synthase and somehow activates the synthase to restore endothelial dysfunction and blood flow disturbance caused by elevated blood glucose.
|
